Anti-serum albumin nano antibody and derivative thereof

CN119032104APending Publication Date: 2024-11-26BIOTHEUS INC
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380031741.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-31
Filing Date
2023-03-31
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing antibody drugs have short half-lives in the body, leading to increased administration frequency, and chemical modification methods such as PEG modification may reduce antibody activity and efficacy.

Method used

Develop anti-serum albumin Nanobodies with high binding activity and pH-independent binding, utilize the FcRn-mediated recycling mechanism to extend the in vivo half-life of the Nanobodies, and conjugate with drugs to extend the drug half-life.

Benefits of technology

The nanobody has achieved good stability and tissue infiltration, flexible administration methods, and a high degree of humanization. It can significantly extend the half-life of the drug in the body, reduce the frequency of administration, and improve the drug efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000049_0000
    Figure 00000049_0000
Patent Text Reader

Abstract

The invention relates to a nano-antibody specifically binding to serum albumin or an antigen-binding fragment thereof, a derivative containing the nano-antibody or the antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a host cell containing the antibody or the antigen-binding fragment thereof, and related applications. Furthermore, this invention relates to the therapeutic use of these antibodies or antigen-binding fragments thereof, or of said derivatives.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-serum albumin nanoantibodies and their derivatives Technical Field

[0001] The present invention relates to Nanobodies or antigen-binding fragments thereof that specifically bind to serum albumin, derivatives containing such Nanobodies or antigen-binding fragments thereof, nucleic acids encoding such antibodies or antigen-binding fragments thereof, host cells containing such antibodies or antigen-binding fragments thereof, and related uses. Furthermore, the invention relates to the therapeutic uses of these antibodies or antigen-binding fragments thereof, or such derivatives. Background Art

[0002] With the advancement of technology, antibody drugs have long become important disease treatments independent of chemical drugs, cell therapies, and other approaches. In antibody drug development, pharmacokinetics (PK) is a crucial area that describes the body's response to antibodies, including absorption, distribution, and clearance. Half-life is a key PK parameter. Generally, a longer in vivo half-life can improve the efficacy of antibodies, but it may also increase toxicity. Tight binding to certain targets can lead to rapid internalization and intracellular degradation of antibodies, shortening their in vivo half-life.

[0003] Extending the half-life of macromolecular drugs in vivo can reduce the frequency of dosing while increasing the duration of the drug's action, thereby reducing the patient's medical burden. Current approaches to extend drug efficacy include polyethylene glycol (PEG) modification and transferrin fusion, but these chemical approaches have drawbacks. For example, PEG may shield or block the antigen-binding sites of antibodies, reducing the efficacy of antibodies or therapeutic proteins, and even potentially causing loss of antibody activity.

[0004] Human serum albumin (HSA) is the most abundant protein in human plasma, accounting for approximately half of serum proteins. It is water-soluble and exists as a monomer. Serum albumin has a half-life of approximately 21 days in vivo. It is composed of 585 amino acids and has a molecular weight of approximately 66.5 kDa. Human serum albumin is stable, safe, non-toxic, and has low immunogenicity, making it an ideal drug carrier. For antibody drugs, HSA can be modified to increase drug half-life and improve patient compliance.

[0005] The recycling mechanism of HSA is similar to that of IgG, both mediated by FcRn. HSA and IgG are internalized into vascular endothelial cells through pinocytosis. The endosomal pH is approximately 6.0, which promotes the binding of membrane-bound FcRn to HSA. HSA is then recycled to the top or bottom of the endothelial cells. Through exocytosis, at a blood pH of 7.4, the membrane-bound FcRn and HSA rapidly dissociate for recycling.

[0006] Summary of the Invention

[0007] After extensive research, the inventors of this application have screened and obtained a series of anti-serum albumin Nanobodies that have high binding activity to serum albumin and cross-reactivity with human, monkey, and / or mouse serum albumin. In particular, the binding of the Nanobodies of the present invention to serum albumin is pH-independent and can effectively participate in the FcRn-mediated serum albumin circulation, thereby extending the in vivo half-life of the Nanobodies. Therefore, the Nanobodies of the present application can be coupled (e.g., fused) to drug molecules (e.g., polypeptide drugs) to extend the in vivo half-life of the drug molecules.

[0008] In addition, the nanoantibodies have the characteristics of small molecular weight and good stability. Compared with traditional common normal antibodies, they have many advantages in drug research and development, such as good tissue infiltration, flexible administration methods, high degree of humanization, and easy recombinant protein transformation.

[0009] Based on this, the present application also provides a composition containing the nanobody or its antigen-binding fragment, a nucleic acid encoding the nanobody or its antigen-binding fragment and a host cell containing the same, as well as related uses.

[0010] Nanobodies and their antigen-binding fragments

[0011] Thus, in one aspect, the present application provides a Nanobody or an antigen-binding fragment thereof that is capable of specifically binding to serum albumin, said Nanobody or antigen-binding fragment thereof comprising:

[0012] (a) CDR1 having a structure selected from the group consisting of: X1X2X3LX4YYX5 (Formula I, SEQ ID NO: 72), SGFTLDYYA (SEQ ID NO: 30), GSIWGIYH (SEQ ID NO: 37), GFTFSIYS (SEQ ID NO: 31), GSIFTFYR (SEQ ID NO: 33);

[0013] (b) CDR2 having a structure selected from the group consisting of: IX6SSGGX7X8 (Formula II, SEQ ID NO: 73), ITVDGST (SEQ ID NO: 46), ISSGGSP (SEQ ID NO: 40), and ITTDTST (SEQ ID NO: 42);

[0014] (c) CDR3 having a structure selected from the group consisting of: AAAX9LECRTX 10 X 11 X 12 X 13 YX 14 Y (Formula III, SEQ ID NO:74), AAATX15 ECRGRSSSYDY (Formula IV, SEQ ID NO:75), AAALLECRVRSWPSDN (SEQ ID NO:49), AAAVLECRAAEYVNS (SEQ ID NO:54), DIRNVGGDY (SEQ ID NO:57), SPITSIFKA (SEQ ID NO:48), NVRNVERDY (SEQ ID NO:50);

[0015] in,

[0016] X1 is selected from the group consisting of (i) amino acid residues G, R and (ii) amino acid residues that are conservative substitutions relative to (i);

[0017] X2 is selected from the group consisting of (i) amino acid residues F, A, S, E and (ii) amino acid residues that are conservative substitutions relative to (i);

[0018] X3 is selected from the group consisting of (i) amino acid residues T, Q and (ii) amino acid residues that are conservative substitutions relative to (i);

[0019] X4 is selected from (i) amino acid residues D, E and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0020] X5 is selected from (i) amino acid residue A and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0021] X6 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i);

[0022] X7 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i);

[0023] X8 is selected from the group consisting of (i) amino acid residue T and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0024] X9 is selected from the group consisting of (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i);

[0025] X 10 selected from (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i);

[0026] X 11 selected from (i) amino acid residues V, I, L and (ii) amino acid residues that are conservative substitutions relative to (i);

[0027] X 12selected from the group consisting of (i) amino acid residues R, V, T and (ii) amino acid residues that are conservative substitutions relative to (i);

[0028] X 13 selected from (i) amino acid residues G, E and (ii) amino acid residues that are conservative substitutions relative to (i);

[0029] X 14 selected from (i) amino acid residues D, A and (ii) amino acid residues that are conservative substitutions relative to (i);

[0030] X 15 Selected from (i) amino acid residues L, F and (ii) amino acid residues that are conservative substitutions relative to (i).

[0031] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises a CDR1 as shown in any one of SEQ ID NOs: 30-38; a CDR2 as shown in any one of SEQ ID NOs: 39-46; and a CDR3 as shown in any one of SEQ ID NOs: 47-59.

[0032] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises:

[0033] (a) CDR1 having the structure shown as X1X2X3LX4YYX5 (Formula I, SEQ ID NO: 72) or SGFTLDYYA (SEQ ID NO: 30);

[0034] (b) CDR2 having the structure shown as IX6SSGGX7X8 (Formula II, SEQ ID NO: 73);

[0035] (c) CDR3 having a structure selected from the group consisting of: AAAX9LECRTX 10 X 11 X 12 X 13 YX 14 Y (Formula III, SEQ ID NO:74), AAATX 15 ECRGRSSSYDY (Formula IV, SEQ ID NO:75), AAALLECRVRSWPSDN (SEQ ID NO:49), AAAVLECRAAEYVNS (SEQ ID NO:54);

[0036] in,

[0037] X1 is selected from the group consisting of (i) amino acid residues G, R and (ii) amino acid residues that are conservative substitutions relative to (i);

[0038] X2 is selected from the group consisting of (i) amino acid residues F, A, S, E and (ii) amino acid residues that are conservative substitutions relative to (i);

[0039] X3 is selected from the group consisting of (i) amino acid residues T, Q and (ii) amino acid residues that are conservative substitutions relative to (i);

[0040] X4 is selected from (i) amino acid residues D, E and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0041] X5 is selected from (i) amino acid residue A and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0042] X6 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i);

[0043] X7 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i);

[0044] X8 is selected from the group consisting of (i) amino acid residue T and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0045] X9 is selected from the group consisting of (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i);

[0046] X 10 selected from (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i);

[0047] X 11 selected from (i) amino acid residues V, I, L and (ii) amino acid residues that are conservative substitutions relative to (i);

[0048] X 12 selected from the group consisting of (i) amino acid residues R, V, T and (ii) amino acid residues that are conservative substitutions relative to (i);

[0049] X 13 selected from (i) amino acid residues G, E and (ii) amino acid residues that are conservative substitutions relative to (i);

[0050] X 14 selected from (i) amino acid residues D, A and (ii) amino acid residues that are conservative substitutions relative to (i);

[0051] X 15 Selected from (i) amino acid residues L, F and (ii) amino acid residues that are conservative substitutions relative to (i).

[0052] In certain embodiments, X1 is selected from amino acid residues G or R; X2 is selected from amino acid residues F, A, S or E; X3 is selected from amino acid residues T or Q; X4 is selected from amino acid residues D or E; X5 is amino acid residue A; X6 is selected from amino acid residues A or S; X7 is selected from amino acid residues A or S; X8 is amino acid residue T; X9 is selected from amino acid residues T or V; X 10 is selected from amino acid residues T or V; X 11 is selected from amino acid residues V, I or L; X 12 is selected from amino acid residues R, V or T; X 13 Selected from amino acid residues G or E; X 14 is selected from amino acid residues D or A; X 15 is selected from amino acid residues L or F.

[0053] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in any one of SEQ ID NOs: 30, 32, 34-36, 38; a CDR2 as shown in any one of SEQ ID NOs: 39, 41, 43-45; and a CDR3 as shown in any one of SEQ ID NOs: 47, 49, 51-56, 58-59.

[0054] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises:

[0055] (a) CDR1 having the structure shown as X1X2X3LX4YYX5 (Formula I, SEQ ID NO: 72) or SGFTLDYYA (SEQ ID NO: 30);

[0056] (b) CDR2 having the structure shown as IX6SSGGX7X8 (Formula II, SEQ ID NO: 73);

[0057] (c) CDR3 having a structure selected from the group consisting of: AAAX9LECRTX 10 X 11 X 12 X 13 YX 14 Y (Formula III, SEQ ID NO:74), AAATX 15 ECRGRSSSYDY (Formula IV, SEQ ID NO:75), AAALLECRVRSWPSDN (SEQ ID NO:49), AAAVLECRAAEYVNS (SEQ ID NO:54);

[0058] in,

[0059] X1 is selected from the group consisting of (i) amino acid residues G, R and (ii) amino acid residues that are conservative substitutions relative to (i);

[0060] X2 is selected from the group consisting of (i) amino acid residues F, E, S and (ii) amino acid residues that are conservative substitutions relative to (i);

[0061] X3 is selected from the group consisting of (i) amino acid residue T and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0062] X4 is selected from (i) amino acid residue D and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0063] X5 is selected from (i) amino acid residue A and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0064] X6 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i);

[0065] X7 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i);

[0066] X8 is selected from the group consisting of (i) amino acid residue T and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0067] X9 is selected from the group consisting of (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i);

[0068] X 10 selected from (i) amino acid residue V and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0069] X 11 selected from (i) amino acid residues V, I and (ii) amino acid residues that are conservative substitutions relative to (i);

[0070] X 12 selected from (i) amino acid residues R, V and (ii) amino acid residues that are conservative substitutions relative to (i);

[0071] X 13 selected from (i) amino acid residues G, E and (ii) amino acid residues that are conservative substitutions relative to (i);

[0072] X 14 selected from (i) amino acid residue D and (ii) an amino acid residue that is a conservative substitution relative to (i);

[0073] X 15 Selected from (i) amino acid residues L, F and (ii) amino acid residues that are conservative substitutions relative to (i).

[0074] In certain embodiments, X1 is selected from amino acid residues G or R; X2 is selected from amino acid residues F, S or E; X3 is amino acid residue T; X4 is amino acid residue D; X5 is amino acid residue A; X6 is selected from amino acid residues A or S; X7 is selected from amino acid residues A or S; X8 is amino acid residue T; X9 is selected from amino acid residues T or V; X 10 is the amino acid residue V; X 11 is selected from amino acid residues V or I; X 12 is selected from amino acid residues R or V; X 13 Selected from amino acid residues G or E; X 14 is the amino acid residue D; X 15 is selected from amino acid residues L or F.

[0075] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in any one of SEQ ID NOs: 30, 32, 34-36; a CDR2 as shown in any one of SEQ ID NOs: 39, 41, 43-45; and a CDR3 as shown in any one of SEQ ID NOs: 47, 49, 51, 52, 54-56, 58.

[0076] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises:

[0077] (a) CDR1 having: a sequence as shown in SEQ ID NO: 32, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 32;

[0078] (b) CDR2 having: a sequence as shown in SEQ ID NO: 41, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 41; and

[0079] (c) CDR3 having: a sequence as shown in SEQ ID NO: 49, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 49.

[0080] In certain embodiments, the substitutions are conservative substitutions.

[0081] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 32, a CDR2 as shown in SEQ ID NO: 41, and a CDR3 as shown in SEQ ID NO: 49.

[0082] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises:

[0083] (a) CDR1 having: a sequence as shown in SEQ ID NO: 32 or 34, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence as shown in SEQ ID NO: 32 or 34;

[0084] (b) CDR2 having: a sequence as shown in SEQ ID NO: 43, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 43; and

[0085] (c) CDR3 having: a sequence as shown in SEQ ID NO: 52, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 52.

[0086] In certain embodiments, the substitutions are conservative substitutions.

[0087] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises:

[0088] (a) CDR1 having the structure X1X2X3LX4YYX5 (Formula I, SEQ ID NO: 72), wherein X1 is an amino acid residue G; X2 is selected from (i) an amino acid residue F or E and (ii) an amino acid residue that is a conservative substitution relative to (i); X3 is an amino acid residue T; X4 is an amino acid residue D; and X5 is an amino acid residue A;

[0089] (b) CDR2, which has the structure shown as IASSGGST (SEQ ID NO: 43);

[0090] (c) CDR3, which has the structure shown as AAAVLECRTVVRGYDY (SEQ ID NO: 52).

[0091] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 32 or 34; a CDR2 as shown in SEQ ID NO: 43; and a CDR3 as shown in SEQ ID Ns: 52.

[0092] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises:

[0093] (a) CDR1 having: a sequence as shown in SEQ ID NO: 37, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 37;

[0094] (b) CDR2 having: a sequence as shown in SEQ ID NO: 46, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 46; and

[0095] (c) CDR3 having: a sequence as shown in SEQ ID NO: 57, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 57.

[0096] In certain embodiments, the substitutions are conservative substitutions.

[0097] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 37, a CDR2 as shown in SEQ ID NO: 46, and a CDR3 as shown in SEQ ID NO: 57.

[0098] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises:

[0099] (a) CDR1 having: a sequence as shown in SEQ ID NO: 31, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 31;

[0100] (b) CDR2 having: a sequence as shown in SEQ ID NO: 40, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 40; and

[0101] (c) CDR3 having: a sequence as shown in SEQ ID NO: 48, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 48.

[0102] In certain embodiments, the substitutions are conservative substitutions.

[0103] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 31, a CDR2 as shown in SEQ ID NO: 40, and a CDR3 as shown in SEQ ID NO: 48.

[0104] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises:

[0105] (a) CDR1 having: a sequence as shown in SEQ ID NO: 33, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 33;

[0106] (b) CDR2 having: a sequence as shown in SEQ ID NO: 42, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 42; and

[0107] (c) CDR3 having: a sequence as shown in SEQ ID NO: 50, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 50.

[0108] In certain embodiments, the substitutions are conservative substitutions.

[0109] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 33, a CDR2 as shown in SEQ ID NO: 42, and a CDR3 as shown in SEQ ID NO: 50.

[0110] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises:

[0111] (1) CDR1 as set forth in SEQ ID NO:30; CDR2 as set forth in SEQ ID NO:39; and CDR3 as set forth in SEQ ID NO:47;

[0112] (2) CDR1 as set forth in SEQ ID NO:31; CDR2 as set forth in SEQ ID NO:40; and CDR3 as set forth in SEQ ID NO:48;

[0113] (3) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:41; and CDR3 as set forth in SEQ ID NO:49;

[0114] (4) CDR1 as set forth in SEQ ID NO:33; CDR2 as set forth in SEQ ID NO:42; and CDR3 as set forth in SEQ ID NO:50;

[0115] (5) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:43; and CDR3 as set forth in SEQ ID NO:51;

[0116] (6) CDR1 as set forth in SEQ ID NO: 32 or 34; CDR2 as set forth in SEQ ID NO: 43; and CDR3 as set forth in SEQ ID NO: 52;

[0117] (7) CDR1 as set forth in SEQ ID NO:35; CDR2 as set forth in SEQ ID NO:43; and CDR3 as set forth in SEQ ID NO:52;

[0118] (8) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:43; and CDR3 as set forth in SEQ ID NO:53;

[0119] (9) CDR1 as set forth in SEQ ID NO:36; CDR2 as set forth in SEQ ID NO:41; and CDR3 as set forth in SEQ ID NO:54;

[0120] (10) CDR1 as set forth in SEQ ID NO:35; CDR2 as set forth in SEQ ID NO:44; and CDR3 as set forth in SEQ ID NO:55;

[0121] (11) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:45; and CDR3 as set forth in SEQ ID NO:56;

[0122] (12) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:41; and CDR3 as set forth in SEQ ID NO:52;

[0123] (13) CDR1 as set forth in SEQ ID NO:37; CDR2 as set forth in SEQ ID NO:46; and CDR3 as set forth in SEQ ID NO:57;

[0124] (14) CDR1 as shown in SEQ ID NO: 32; CDR2 as shown in SEQ ID NO: 41; and CDR3 as shown in SEQ ID NO: 58; or

[0125] (15) CDR1 as shown in SEQ ID NO:38; CDR2 as shown in SEQ ID NO:41; and CDR3 as shown in SEQ ID NO:59.

[0126] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises an amino acid sequence selected from the group consisting of:

[0127] (i) a sequence as shown in any one of SEQ ID NOs: 1-3, 7-9, 14-24, 28-29;

[0128] (ii) a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) compared to the sequence shown in any one of SEQ ID NOs: 1-3, 7-9, 14-24, 28-29; or

[0129] (iii) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 1-3, 7-9, 14-24, 28-29.

[0130] In certain embodiments, the substitutions are conservative substitutions.

[0131] In certain embodiments, the Nanobody or antigen-binding fragment thereof is humanized.

[0132] In certain embodiments, the Nanobody or antigen-binding fragment thereof further comprises a heavy chain framework region of a human immunoglobulin (for example, a heavy chain framework region contained in the amino acid sequence encoded by a human heavy chain germline antibody gene), which heavy chain framework region optionally comprises one or more (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) back mutations from human residues to camel residues.

[0133] In certain embodiments, the Nanobody or antigen-binding fragment thereof comprises an amino acid sequence selected from the group consisting of:

[0134] (i) a sequence as shown in any one of SEQ ID NOs: 4-6, 10-13, 25-27, and 78;

[0135] (ii) a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) compared to the sequence shown in any one of SEQ ID NOs: 4-6, 10-13, 25-27, 78; or

[0136] (iii) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 4-6, 10-13, 25-27, 78.

[0137] In certain embodiments, the substitutions are conservative substitutions.

[0138] In certain embodiments, the serum albumin is selected from human serum albumin (HSA), murine serum albumin (MSA) and / or cynomolgus monkey serum albumin (CSA).

[0139] In certain embodiments, the binding of said Nanobody or antigen-binding fragment thereof to said serum albumin is pH-independent.

[0140] In certain embodiments, the Nanobody or antigen-binding fragment thereof is capable of specifically binding to the serum albumin in the range of pH 5-8 (eg pH 5.5-7.4).

[0141] polypeptide constructs

[0142] On the other hand, the present application also provides a polypeptide construct that specifically binds to serum albumin, which comprises the Nanobody or antigen-binding fragment thereof as described above, and an immunoglobulin Fc domain.

[0143] As used herein, the Fc domain, also referred to as the Fc region, refers to the portion of the heavy chain constant region comprising CH2 and CH3. In some embodiments, the Fc domain comprises a hinge, CH2, and CH3. When the Fc domain comprises a hinge, the hinge mediates dimerization between two Fc-containing polypeptides. The Fc domain can be of any antibody heavy chain constant region isotype. In some embodiments, the Fc domain is IgG1, IgG2, IgG3, or IgG4.

[0144] In certain embodiments, the Fc domain included in the polypeptide construct of the present invention is a native Fc region, which comprises an amino acid sequence consistent with the amino acid sequence of the Fc region found in nature. For example, the Fc domain can be a native sequence human IgG1 Fc region, a native sequence human IgG2 Fc region, a native sequence human IgG3 Fc region, or a native sequence human IgG4 Fc region. A native Fc region may have effector functions. Exemplary "effector functions" include binding to Fc receptors; Clq binding and complement-dependent cytotoxicity (CDC); antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation, etc. Functional changes can be produced by replacing at least one amino acid residue in the native Fc region with a different residue or chemical modification, for example, changing the affinity of the antibody for effector ligands (such as FcR or complement C1q), thereby changing the effector function (e.g., reducing or enhancing).

[0145] Therefore, in certain embodiments, the Fc domain comprised by the polypeptide construct of the present invention may also be a variant Fc region, which may comprise one or more (e.g., 1-10, such as 1-5) amino acid mutations or chemical modifications compared to a native Fc region to alter one or more of the following properties of the antibody of the present invention: Fc receptor binding, antibody glycosylation, the number of cysteine ​​residues, effector cell function, or complement function, etc.

[0146] In certain embodiments, the Fc domain comprised by the polypeptide construct of the present invention has ADCC activity. In certain embodiments, the Fc domain comprised by the polypeptide construct of the present invention does not have ADCC activity.

[0147] In certain embodiments, the immunoglobulin Fc domain is linked to the N-terminus and / or C-terminus (eg, the C-terminus) of the Nanobody or antigen-binding fragment thereof, optionally via a peptide linker.

[0148] In certain embodiments, the immunoglobulin Fc domain is the Fc domain of IgG (eg, the Fc domain of IgG1).

[0149] In certain embodiments, the immunoglobulin Fc domain comprises the sequence of SEQ ID NO: 68, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity thereto, or a sequence having one or more amino acid substitutions, deletions, or additions (e.g., 1, 2, 3, 4, or 5 amino acid substitutions, deletions, or additions) thereto.

[0150] In certain embodiments, the serum albumin is selected from human serum albumin (HSA), murine serum albumin (MSA) and / or cynomolgus monkey serum albumin (CSA).

[0151] In certain embodiments, the binding of the polypeptide construct to the serum albumin is pH independent.

[0152] In certain embodiments, the polypeptide construct is capable of specifically binding to the serum albumin in the pH range of 5-8 (eg, pH 5.5-7.4).

[0153] Fusion protein

[0154] On the other hand, the present application also provides a fusion protein comprising a Nanobody or antigen-binding fragment thereof as described above or a polypeptide construct as described above, and an additional peptide domain.

[0155] In certain embodiments, the additional peptide domain is selected from polypeptide domains having a therapeutic effect.

[0156] In certain embodiments, the additional polypeptide domain is linked to the N-terminus and / or C-terminus of said Nanobody or antigen-binding fragment thereof or said polypeptide construct, optionally via a peptide linker.

[0157] Isolated nucleic acid molecules

[0158] In another aspect, the present application also provides an isolated nucleic acid molecule encoding a Nanobody or antigen-binding fragment thereof as described above, a polypeptide construct as described above, or a fusion protein as described above.

[0159] carrier

[0160] In another aspect, the present application also provides a vector comprising the nucleic acid molecule as described above. In certain embodiments, the vector is a cloning vector or an expression vector.

[0161] host cells

[0162] On the other hand, the application also provides a host cell comprising a nucleic acid molecule as described above or a vector as described above. Such host cells include, but are not limited to, prokaryotic cells such as bacterial cells (such as Escherichia coli cells), and eukaryotic cells such as fungal cells (such as yeast cells), insect cells, plant cells and animal cells (such as mammalian cells, such as mouse cells, human cells, etc.).

[0163] Preparation method

[0164] The nanobodies or polypeptide constructs or fusion proteins of the present invention can be prepared by various methods known in the art, for example, by genetic engineering recombinant technology. For example, a DNA molecule encoding a nanobody or polypeptide construct or fusion protein of the present invention is obtained by chemical synthesis or PCR amplification. The resulting DNA molecule is inserted into an expression vector and then transfected into a host cell. The transfected host cell is then cultured under specific conditions and expresses the antibody or polypeptide construct or fusion protein of the present invention.

[0165] The antigen-binding fragments of the present invention can be obtained by hydrolyzing intact nanobody molecules (see Morimoto et al., J. Biochem. Biophys. Methods 24: 107-117 (1992) and Brennan et al., Science 229: 81 (1985)). In addition, these antigen-binding fragments can also be produced directly by recombinant host cells (reviewed in Hudson, Curr. Opin. Immunol. 11: 548-557 (1999); Little et al., Immunol. Today, 21: 364-370 (2000)). Those skilled in the art are fully aware of other techniques for preparing these antigen-binding fragments.

[0166] On the other hand, the present application also provides a method for preparing a Nanobody or an antigen-binding fragment thereof as described above, a polypeptide construct as described above, or a fusion protein as described above, which comprises culturing a host cell as described above under conditions that allow protein expression, and recovering the Nanobody or its antigen-binding fragment or the polypeptide construct from the cultured host cell culture.

[0167] Bispecific or multispecific antibodies

[0168] In another aspect, the present application also provides a bispecific or multispecific antibody comprising a Nanobody or antigen-binding fragment thereof as described above or a polypeptide construct as described above.

[0169] In certain embodiments, the bispecific or multispecific antibody specifically binds serum albumin and additionally specifically binds one or more other targets.

[0170] In certain embodiments, the bispecific or multispecific antibody further comprises at least one second antibody or antigen-binding fragment thereof having a second binding specificity for a second target.

[0171] In certain embodiments, the bispecific or multispecific antibody comprises:

[0172] (i) a Nanobody or antigen-binding fragment thereof as described above or a polypeptide construct as described above (for example, a Nanobody or antigen-binding fragment thereof or polypeptide construct containing a sequence as shown in any one of SEQ ID NOs: 10, 4, 78) as the first antigen-specific binding domain;

[0173] (ii) a second antigen-specific binding domain (e.g., Fab) comprising a light chain as shown in SEQ ID NO: 79 and a heavy chain as shown in SEQ ID NO: 80;

[0174] as well as,

[0175] (iii) a third antigen-specific binding domain (e.g., Nanobody VHH) as shown in SEQ ID NO: 81.

[0176] In certain embodiments, the bispecific or multispecific antibody comprises a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises (e.g., from N-terminus to C-terminus): a light chain or heavy chain (e.g., VH and CH1) of the second antigen-specific binding domain, the third antigen-specific binding domain, and the first antigen-specific binding domain; and the second polypeptide chain comprises (e.g., from N-terminus to C-terminus): a heavy chain (e.g., VH and CH1) or light chain of the second antigen-specific binding domain, the third antigen-specific binding domain; wherein the first polypeptide chain is paired with the second polypeptide chain to form a complete second antigen-specific binding domain. In certain embodiments, each domain in the first polypeptide chain and / or the second polypeptide chain is connected by a linker (e.g., a peptide linker comprising one or more glycine and / or one or more serine).

[0177] In certain embodiments, the bispecific or multispecific antibody comprises:

[0178] (1) a first peptide having a sequence as shown in SEQ ID NO: 69, and a second peptide having a sequence as shown in SEQ ID NO: 76;

[0179] (2) a first peptide having a sequence as shown in SEQ ID NO: 70, and a second peptide having a sequence as shown in SEQ ID NO: 76;

[0180] or,

[0181] (3) a first peptide having a sequence as shown in SEQ ID NO: 71, and a second peptide having a sequence as shown in SEQ ID NO: 76.

[0182] In certain embodiments, the first peptide is present in a first peptide chain, and the second peptide is present in a second peptide chain; in certain embodiments, the first peptide chain forms a complex with the second peptide chain.

[0183] Conjugate

[0184] In another aspect, the present application also provides a conjugate comprising a Nanobody or antigen-binding fragment thereof as described above or a polypeptide construct as described above, and a therapeutic agent linked to the Nanobody or antigen-binding fragment thereof or polypeptide construct.

[0185] In certain embodiments, the therapeutic agent is selected from an anti-tumor drug, such as a cytotoxic agent, a hormonal drug, a biological response modifier, another antibody or an antigen-binding fragment thereof.

[0186] Pharmaceutical composition

[0187] On the other hand, the present application also provides a pharmaceutical composition comprising a Nanobody or antigen-binding fragment thereof, a polypeptide construct, a fusion protein, an isolated nucleic acid molecule, a vector, a host cell, a bispecific or multispecific antibody or a conjugate as described above.

[0188] In certain embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0189] In certain exemplary embodiments, the pharmaceutically acceptable carrier and / or excipient comprises a sterile injectable liquid (e.g., an aqueous or non-aqueous suspension or solution). In certain exemplary embodiments, such sterile injectable liquid is selected from water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), a solution containing a surfactant (e.g., 0.01% polysorbate 20), a pH buffered solution (e.g., phosphate buffered solution), Ringer's solution, and any combination thereof.

[0190] In certain embodiments, the pharmaceutical composition comprises a Nanobody or antigen-binding fragment thereof, a polypeptide construct, or a nucleic acid molecule, vector or host cell encoding the Nanobody or antigen-binding fragment thereof or polypeptide construct as described above.

[0191] In certain embodiments, the pharmaceutical composition comprises the fusion protein as described above, or a nucleic acid molecule, vector or host cell encoding the fusion protein.

[0192] In certain embodiments, the pharmaceutical composition comprises the bispecific or multispecific antibody as described above, or a nucleic acid molecule, vector, or host cell encoding the bispecific or multispecific antibody.

[0193] In certain embodiments, the pharmaceutical composition comprises a conjugate as described above.

[0194] use

[0195] On the other hand, the present application also provides the use of the nanobody or antigen-binding fragment thereof, polypeptide construct, fusion protein, isolated nucleic acid molecule, vector, host cell, bispecific or multispecific antibody or conjugate, or pharmaceutical composition as described above for the preparation of a drug.

[0196] In certain embodiments, the drug is capable of directly or indirectly participating in FcRn-mediated serum albumin recycling in a subject.

[0197] In certain embodiments, said drug exhibits a prolonged half-life in vivo relative to the corresponding drug lacking said Nanobody or antigen-binding fragment thereof.

[0198] In certain embodiments, the drug is a protein drug.

[0199] In certain embodiments, the subject is a mammal, such as a human, mouse, or cynomolgus monkey.

[0200] Methods for prolonging the half-life of drugs in vivo

[0201] On the other hand, the present application also provides a method for prolonging the in vivo half-life of a drug, comprising: linking the nanobody or antigen-binding fragment thereof as described above or the polypeptide construct as described above to the drug.

[0202] In certain embodiments, said extension of in vivo half-life is relative to the in vivo half-life of said drug in the absence of said Nanobody or antigen-binding fragment thereof.

[0203] In certain embodiments, the drug is selected from macromolecular drugs (eg, polypeptide drugs).

[0204] In certain embodiments, the subject is a mammal, such as a human, mouse, or cynomolgus monkey.

[0205] Definition of terms

[0206] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the virology, biochemistry, and immunology laboratory procedures used herein are conventional procedures widely used in the respective fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.

[0207] When the terms "for example," "such as," "including," "including," "comprising," or variations thereof are used herein, these terms will not be considered as limiting terms, but will be interpreted to mean "but not limited to" or "not limited to."

[0208] The terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0209] As used herein, the term "nanobody" has the meaning generally understood by those skilled in the art and refers to an antibody fragment consisting of a single monomeric variable antibody domain (e.g., a single heavy chain variable region), typically derived from the variable region of a heavy chain antibody (e.g., a camelid antibody or a shark antibody). Typically, a nanobody consists of four framework regions and three complementarity determining regions, with a structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. A nanobody may be truncated at the N-terminus or C-terminus so that it contains only part of FR1 and / or FR4, or lacks one or two of those framework regions, as long as it substantially maintains antigen binding and specificity. Nanobodies are also referred to as single-domain antibodies (sdAbs), and the two are used interchangeably.

[0210] As used herein, the term "antigen-binding fragment" of a Nanobody refers to a polypeptide comprising a fragment of a Nanobody that retains the ability to specifically bind to the same antigen bound by the Nanobody and / or competes with the Nanobody for specific binding to the antigen, which is also referred to as an "antigen-binding portion". See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of the antibodies of the invention can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of the Nanobodies of the invention. In some embodiments, the "antigen-binding fragment" of such a Nanobody may be truncated at the N-terminus or C-terminus compared to a full-length Nanobody so that it only comprises part of FR1 and / or FR4, or lacks one or both of those framework regions, as long as it substantially retains antigen binding and specificity.

[0211] Antigen-binding fragments of Nanobodies can be obtained from a given Nanobody (such as the Nanobodies provided herein) using conventional techniques known to those skilled in the art (for example, recombinant DNA techniques or enzymatic or chemical cleavage methods), and screened for specificity in the same manner as for intact Nanobodies.

[0212] In this document, unless the context clearly indicates otherwise, when referring to the term "Nanobody" it includes not only whole Nanobodies but also antigen-binding fragments of Nanobodies.

[0213] As used herein, the term "complementarity determining region" or "CDR" refers to the amino acid residues in the variable region of an antibody that are responsible for antigen binding. In nanobodies, there are three CDRs, designated CDR1, CDR2, and CDR3. The precise boundaries of these CDRs can be defined according to various numbering systems known in the art, for example, according to the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:878-883), or the IMGT numbering system (Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003). For a given Nanobody, a person skilled in the art will readily identify the CDRs defined by each numbering system. Moreover, the correspondence between different numbering systems is well known to those skilled in the art (e.g., see Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003). In this context, the CDRs of a Nanobody are preferably identified by the IMGT numbering system.

[0214] As used herein, the term "framework region" or "FR" residues refers to those amino acid residues in an antibody variable region other than the CDR residues as defined above.

[0215] As used herein, the term "Fc domain" or "Fc region" means a portion of the heavy chain constant region comprising CH2 and CH3. The Fc fragment of an antibody has a variety of different functions, but is not involved in antigen binding. The "effector functions" mediated by the Fc region include Fc receptor binding; Clq binding and complement-dependent cytotoxicity (CDC); antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation, among others. In some embodiments, the Fc region comprises a hinge, CH2, and CH3. When the Fc region comprises a hinge, the hinge regulates the dimerization between two Fc-containing polypeptides. The Fc region can be of any antibody heavy chain constant region isotype, such as IgG1, IgG2, IgG3, or IgG4.

[0216] The Fc domain may include both a native Fc region and a variant Fc region. A native Fc region comprises an amino acid sequence that is consistent with the amino acid sequence of an Fc region found in nature, for example, a native sequence human Fc region includes a native sequence human IgG1 Fc region (non-A and A allotypes); a native sequence human IgG2 Fc region; a native sequence human IgG3 Fc region; and a native sequence human IgG4 Fc region, as well as naturally occurring variants thereof. A variant Fc region comprises an amino acid sequence that differs from the amino acid sequence of a native sequence Fc region due to at least one amino acid modification. In some embodiments, a variant Fc region may have an effector function (e.g., Fc receptor binding, antibody glycosylation, the number of cysteine ​​residues, effector cell function, or complement function) that is altered compared to a native Fc region.

[0217] As used herein, the term "humanized antibody" refers to a non-human antibody that has been genetically engineered and whose amino acid sequence has been modified to improve the homology with the sequence of a human antibody. Generally speaking, all or part of the CDR region of a humanized antibody comes from a non-human antibody (donor antibody), and all or part of the non-CDR region (e.g., variable region FR and / or constant region) comes from a human immunoglobulin (recipient antibody). In certain embodiments, the CDR region of a humanized antibody comes from a non-human antibody (donor antibody), and all or part of the non-CDR region (e.g., variable region FR and / or constant region) comes from a human immunoglobulin (recipient antibody). Humanized antibodies generally retain the expected properties of the donor antibody, including but not limited to, antigen specificity, affinity, reactivity, etc. In the present application, the donor antibody can be a camel-derived antibody with the expected properties (e.g., antigen specificity, affinity, reactivity, etc.). To prepare humanized antibodies, the CDR region of an immune animal can be inserted into a human framework sequence using methods known in the art. In the context of nanobodies, humanized antibodies may refer to humanized VHHs, i.e., VHHs in which one or more framework regions have been substantially replaced by human framework regions. In some cases, certain framework regions (FRs) of human immunoglobulins are replaced by corresponding non-human residues. In addition, humanized VHHs may contain residues that are not found in the original VHH or human framework sequence, but are included to further improve and optimize the performance of the VHH or VHH-containing polypeptide.

[0218] As used herein, the term "identity" is used to refer to the matching of sequences between two polypeptides or between two nucleic acids. In order to determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., a gap can be introduced in the first amino acid sequence or nucleic acid sequence to optimally align with the second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., percent identity = number of identical overlapping positions / total number of positions × 100%). In certain embodiments, the two sequences are the same length.

[0219] The determination of percent identity between two sequences can also be achieved using a mathematical algorithm. A non-limiting example of a mathematical algorithm for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87: 2264-2268, as modified in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90: 5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215: 403.

[0220] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as an antibody and its antigen. The strength or affinity of a specific binding interaction can be measured by the equilibrium dissociation constant (K) of the interaction. D ) indicates. In the present invention, the term "K D ” refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen.

[0221] The specific binding properties between two molecules can be determined using methods known in the art. One method involves measuring the rate of formation and dissociation of the antigen binding site / antigen complex. Both the "association rate constant" (ka or kon) and the "dissociation rate constant" (kdis or koff) can be calculated from the concentration and the actual rates of association and dissociation (see Malmqvist M, Nature, 1993, 361: 186-187). The ratio of kdis / kon is equal to the dissociation constant K D (See Davies et al., Annual Rev Biochem, 1990; 59: 439-473). K can be measured by any effective method. D , kon and kdis values. In certain embodiments, the dissociation constant can be measured in Biacore using surface plasmon resonance (SPR). In addition, the dissociation constant can be measured using bioluminescence interferometry or Kinexa.

[0222] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, it is referred to as an expression vector. A vector can be introduced into a host cell via transformation, transduction, or transfection, allowing the genetic material it carries to be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages, such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomas (such as SV40). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain an origin of replication.

[0223] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.

[0224] As used herein, the term "conservative substitution" means an amino acid substitution that does not adversely affect or change the expected properties of the protein / polypeptide comprising the amino acid sequence. For example, conservative substitutions can be introduced by standard techniques known in the art such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include substitutions of amino acid residues with amino acid residues having similar side chains, such as substitutions of residues physically or functionally similar to corresponding amino acid residues (e.g., having similar size, shape, charge, chemical properties, including the ability to form covalent bonds or hydrogen bonds, etc.). Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, it is preferred to replace a corresponding amino acid residue with another amino acid residue from the same side chain family. Methods for identifying conservative amino acid substitutions are well known in the art (see, e.g., Brummell et al., Biochem. 32: 1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10): 879-884 (1999); and Burks et al. Proc. Natl Acad. Set USA 94: 412-417 (1997), which are incorporated herein by reference).

[0225] The twenty conventional amino acids referred to herein are written in accordance with conventional usage. See, for example, Immunology—A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In the present invention, the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. Also, in the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0226] As used herein, the term "pharmaceutically acceptable carrier and / or excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995) and includes, but is not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers, diluents, agents that maintain osmotic pressure, agents that delay absorption, and preservatives. For example, pH adjusters include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Agents that maintain osmotic pressure include, but are not limited to, sugars, NaCl, and the like. Agents that delay absorption include, but are not limited to, monostearate and gelatin. Diluents include, but are not limited to, water, aqueous buffers (such as buffered saline), alcohols and polyols (such as glycerol), etc. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, etc. Stabilizers have the meaning generally understood by those skilled in the art, and are capable of stabilizing the desired activity of the active ingredient in the drug, including, but not limited to, sodium glutamate, gelatin, SPGA, carbohydrates (such as sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin or casein) or their degradation products (such as lactalbumin hydrolysate), etc. In certain exemplary embodiments, the pharmaceutically acceptable carrier or excipient comprises a sterile injectable liquid (such as an aqueous or non-aqueous suspension or solution). In certain exemplary embodiments, such sterile injectable liquids are selected from water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), a solution containing a surfactant (e.g., 0.01% polysorbate 20), a pH buffered solution (e.g., phosphate buffered solution), Ringer's solution, and any combination thereof.

[0227] As used herein, the term "in vivo half-life" has a meaning well known to those skilled in the art and can generally be defined as the time required for the serum concentration of a molecule in vivo to decrease by 50% (e.g., due to degradation of the ligand and / or clearance or sequestration of the ligand by natural mechanisms). Methods for determining in vivo half-life are well known to those skilled in the art and can be determined, for example, by pharmacokinetic analysis.

[0228] Advantageous Effects of the Invention

[0229] The present invention provides Nanobodies with high binding activity to serum albumin, which have cross-reactivity with human, monkey, and / or mouse serum albumin. In particular, the binding of the Nanobodies of the present invention to serum albumin is pH-independent, and they can effectively participate in the FcRn-mediated serum albumin circulation, thereby extending the in vivo half-life of the Nanobodies. Therefore, the Nanobodies of the present application can be coupled (e.g., fused) to drug molecules (e.g., polypeptide drugs) to extend the in vivo half-life of the drug molecules.

[0230] In addition, the nanoantibodies have the characteristics of small molecular weight and good stability. Compared with traditional common normal antibodies, they have many advantages in drug research and development, such as good tissue infiltration, flexible administration methods, high degree of humanization, and easy recombinant protein transformation.

[0231] The embodiments of the present invention will be described in detail below with reference to the accompanying drawings and examples, but it will be understood by those skilled in the art that the following drawings and examples are intended only to illustrate the present invention and are not intended to limit the scope of the invention. Various objects and advantages of the present invention will become apparent to those skilled in the art based on the following detailed description of the accompanying drawings and preferred embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0232] FIG1 shows the changes in the concentrations of Bi-340-352, Bi-340-353, Bi-340-354, and Bi-340-356 in mouse serum over time. DETAILED DESCRIPTION

[0233] The invention will now be described with reference to the following examples which are intended to illustrate the invention but not to limit it.

[0234] Unless otherwise specified, the molecular biology experimental methods and immunoassays used in the present invention are basically based on the methods described in J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 1989, and F.M. Ausubel et al., Molecular Biology: A Laboratory Manual, 3rd edition, John Wiley & Sons, Inc., 1995. Restriction endonucleases were used according to the conditions recommended by the product manufacturers. It will be appreciated by those skilled in the art that the examples illustrate the present invention by way of example and are not intended to limit the scope of the present invention.

[0235] Example 1: Screening of anti-HSA nanobodies

[0236] 1.1 Construction of Nanobody Library

[0237] Animal Immunization

[0238] Two alpacas were immunized with 1 mg of human serum albumin (HSA) antigen (purchased from AcroBiosystems) mixed with equal volumes of Freund's adjuvant. Immunizations were repeated four times weekly to stimulate B cell expression of antigen-specific nanobodies. Following the four immunizations, 50 ml of alpaca peripheral blood was extracted and lymphocytes were isolated using a lymphocyte separation buffer. Total RNA was extracted using the RNA extraction reagent Trizol (purchased from Invitrogen). Total cDNA from alpaca lymphocytes was obtained by reverse transcription using a cDNA synthesis kit (purchased from Invitrogen).

[0239] Nanobody gene amplification

[0240] Perform the first round of PCR to amplify IgG2 and IgG3 sequences from the cDNA obtained in the previous step. The primers used for amplification are shown in Table 1:

[0241] Table 1. First round PCR primers

[0242] The first-round PCR products were subjected to agarose gel electrophoresis, and the 750 bp fragment was recovered for the second-round VHH sequence amplification. The second-round PCR amplification primers are shown in Table 2:

[0243] Table 2. Second round PCR primers

[0244] Using the second round PCR product as a template, a third round of PCR was performed to add homology arm sequences homologous to the display vector to the VHH gene. The third round of PCR amplification primers are shown in Table 3:

[0245] Table 3. Third round PCR primers

[0246] The target fragment was recovered using a PCR purification kit (purchased from QIAGEN).

[0247] Library construction

[0248] The linearized yeast display vector (artificially synthesized) and the third-round PCR product were mixed and electroporated into Saccharomyces cerevisiae (purchased from ATCC). Anti-HSA nanobody libraries from two animals were constructed and the library capacity was determined. The library capacity was 2.1×10 7 and 3.2×10 7 .

[0249] 1.2 Screening of HSA nanobodies

[0250] Biotinylation of HSA protein

[0251] Dissolve HSA protein (purchased from AcroBiosystems, Cat. No. HSA-H5220) in an appropriate volume of double-distilled water. Following the instructions for the biotin labeling kit (purchased from Thermo), dissolve the biotin and mix with the protein solution. Incubate at 4°C for 2 hours. Remove excess biotin using a desalting column (purchased from Thermo). Column pretreatment and sample collection procedures were performed according to the product instructions.

[0252] MACS enrichment of yeast that specifically binds to HSA

[0253] Inoculate the VHH library constructed in step 1.1 above into SD-CAA amplification medium (1 L of SD-CAA amplification medium containing 6.7 g YNB, 5 g tyrosine, 13.62 g Na2HPO4·12H2O, 7.44 g NaH2PO4, and 2% glucose) and culture overnight at 30°C, 225 rpm. Remove an appropriate amount of yeast cells and centrifuge at 3000 rpm for 5 min (the centrifugation parameters will remain the same throughout this procedure). Remove the medium and resuspend the yeast cells in SD-CAA induction medium. Induce overnight. Determine the library concentration after induction, remove an appropriate amount of yeast cells, and remove the medium by centrifugation. Resuspend the yeast cells in 50 ml of PBS and remove the supernatant by centrifugation. Resuspend the yeast cells in 10 ml of PBS.

[0254] Add biotinylated HSA protein (final concentration 100 mM) obtained as described above, incubate at room temperature for 30 minutes, collect yeast cells by centrifugation, and wash the yeast three times with 50 ml of PBS. Resuspend the yeast cells in 5 ml of washing solution and add 200 μl of SA magnetic beads (purchased from Miltenyi Biotec) and incubate upside down for 10 minutes. Wash the yeast and magnetic bead mixture three times with PBS and add the mixture to an LS purification column (purchased from Miltenyi Biotec). Place the LS purification column on a magnetic stand and wash with PBS to remove non-specifically bound yeast cells. Remove the purification column from the magnetic stand and add PBS to elute the yeast. After centrifugation, transfer the eluted yeast into SD-CAA amplification medium for amplification.

[0255] Obtaining high-affinity yeast cells by flow cytometry sorting

[0256] Yeast cells enriched by MACS were inoculated into SD-CAA expansion medium. Cultured overnight at 30°C and 225 rpm. Yeast cells were resuspended in SD-CAA induction medium and induced overnight. Anti-c-Myc mouse antibody (Thermo, Catalog No. MA1-980) and 100 nM biotinylated HSA antigen were added and incubated for 10 minutes. The yeast were washed three times with PBS and then incubated with goat anti-mouse IgG (H+L) Alexa Fluor Plus 488 fluorescent antibody (Invitrogen, Catalog No. A32723) and streptavidin-APC conjugate fluorescent antibody (Invitrogen, Catalog No. SA1005) for 15 minutes. Cells were resuspended in PBS and sorted using a BD FACSAria II instrument to identify yeast cells with high HSA antigen binding capacity.

[0257] Retrieval of HSA nanobody candidate molecule antibody genes

[0258] Yeast culture fluid with high binding capacity to HSA antigens, obtained by MACS and FACS enrichment, was cultured overnight in SD-CAA amplification medium at 30°C and 225 rpm. Yeast plasmids were extracted using a yeast plasmid extraction kit (purchased from Tiangen). The plasmids were electroporated into Top10 competent cells (purchased from Tiangen), plated on ampicillin-resistant plates, and cultured overnight at 37°C. Monoclonal clones were selected for sequencing to obtain the VHH amino acid sequence, and the CDR region sequence was determined according to the IMGT numbering system. The sequence information of the obtained monoclonal nanobodies is shown in Table 4.

[0259] Example 2. Construction, expression and purification of heavy chain antibodies

[0260] 2.1. Antibody gene construction into pCDNA3.1 expression vector

[0261] The VHH gene sequence was linked to the human IgG1 (LALA mutation) Fc region (amino acid sequence shown in SEQ ID NO: 68) and constructed using homologous recombination enzyme (purchased from Vazyme, Catalog No. c115-02) in the pCDNA3.1 vector linearized with EcoRI / NotI double digestion, following the manufacturer's instructions. The homologous recombination product was transformed into Top10 competent cells, plated on ampicillin-resistant plates, and cultured overnight at 37°C. Single clones were picked for sequencing, and the plasmid was extracted.

[0262] The sequence of SEQ ID NO:68 is as follows:

[0263] 2.2. Cell transfection and protein purification

[0264] Using ExpiCHO TM Using an expression system kit (purchased from Thermo), the extracted plasmid obtained in the above steps was transformed into Expi-CHO cells using the transfection method described in the product instructions. After 5 days of cell culture, the supernatant was collected and the target protein was purified using Protein A magnetic beads (purchased from GenScript). The beads were resuspended in an appropriate volume (1-4 times the volume of the beads) of binding buffer (PBS + 0.1% Tween 20, pH 7.4) and added to the sample to be purified. Incubate at room temperature for 1 hour with gentle shaking. The sample was placed on a magnetic stand (purchased from Beaver), the supernatant was discarded, and the beads were washed three times with binding buffer. Elution buffer (0.1M sodium citrate, pH 3.2) was added at 3-5 times the volume of the beads and shaken at room temperature for 5-10 minutes. The beads were then returned to the magnetic stand, the elution buffer was collected, transferred to a collection tube containing neutralization buffer (1M Tris, pH 8.54), and mixed thoroughly to obtain the target protein.

[0265] Example 3. HSA Antibody Affinity Determination

[0266] ForteBio affinity determination was performed according to existing methods (Estep, P et al., Antibody-antigen affinity and epitope binding determination based on high-throughput methods. MAbs, 2013. 5(2): p. 270-8). Briefly, the sensor was equilibrated offline in assay buffer for 30 minutes, followed by online detection for 60 seconds to establish a baseline. The purified antibody obtained as described above was then loaded online onto the AHQ sensor. The sensor was then exposed to 100 nM HSA antigen (purchased from AcroBiosystems, catalog number: HSA-H5220) for 5 minutes, after which the sensor was transferred to PBS for dissociation for 5 minutes. Kinetic analysis was performed using a 1:1 binding model. Affinity data are shown in Table 5.

[0267] Table 5. Affinity of candidate molecules to HSA

[0268] This example further tested the cross-reactivity of the candidate molecule with serum albumins from different species, including mouse serum albumin (MSA, purchased from AcroBiosystems, Catalog No. MSA-M52H8) and cynomolgus serum albumin (CSA, purchased from AcroBiosystems, Catalog No. CSA-C52H4). The affinity data are shown in Table 6.

[0269] Table 6. Affinity of candidate molecules to MSA / CSA

[0270] Example 4. Construction of humanized anti-HSA antibody

[0271] To reduce the immunogenicity of monoclonal antibodies in humans, three antibodies, HSA-59, HSA-M-27, and HSA-PH-8, were humanized. The humanization method employed the universal VHH humanization framework transplantation method, while partial amino acid mutations in framework 2 were performed according to the method reported in the literature (Vincke, C., et al., Humanized camelid single-domain antibodies and a general strategy for identifying universal humanized nanoantibody scaffolds. J Biol Chem 284(5):3273-3284). The sequence information of the humanized antibodies is shown in Table 7.

[0272] In this study, the humanization levels of HSA-59, HSA-M-27, and HSA-PH-8 and their humanized sequences were evaluated using IMGT (http: / / www.imgt.org). The results are shown in Table 8. The humanization levels of all humanized samples were improved, meeting the requirements for late-stage drug development.

[0273] Table 8. Homology between humanized HSA sequences and humans

[0274] Protein construction, expression, and purification were performed as in Example 2. Protein purity was determined by HPLC, with the results shown in Table 9. The HPLC method was as follows: mobile phase: 150 mM Na₂HPO₄·12H₂O, pH 7.0. Chromatographic conditions: detection wavelength: 280 nm, column temperature: 25°C, flow rate: 0.35 ml / min, detection time: 20 min, Zenix-C SEC-300 column (SEPAX 4.6 × 300 mm, 3 μm).

[0275] Table 9. Purity test results of Anti-HSA humanized antibody

[0276] Example 5. Affinity determination of anti-HSA humanized samples

[0277] 5.1. Affinity determination of humanized antibodies

[0278] In this example, the binding affinity of the purified humanized anti-HSA sample to HSA was detected. The experimental method was the same as that in Example 3. The experimental results are shown in Table 10. The results show that the humanized anti-HSA sample has good binding activity to the HSA protein.

[0279] Table 10. Affinity of humanized molecules to HSA

[0280] In this example, the binding affinity of the purified humanized anti-HSA sample to MSA / CSA was also tested. The experimental method was the same as that in Example 3. The experimental results are shown in Table 11.

[0281] Table 11. Affinity of humanized molecules to MSA / CSA

[0282] 5.2. Affinity determination of humanized antibodies at different pH

[0283] The recycling mechanism of HSA is similar to that of IgG. It is internalized into vascular endothelial cells through pinocytosis. The endosomal pH is around 6.0, which promotes the binding of membrane-bound FcRn to HSA. The endosomal complex is then recycled into the blood. At pH 7.4, the membrane-bound FcRn and HSA rapidly dissociate, allowing HSA to be recycled.

[0284] In this example, the affinity of the purified humanized anti-HSA sample to HSA under different pH conditions was tested. The experimental method was the same as that in Example 3. The experimental results are shown in Table 12. The results show that the humanized anti-HSA sample has good binding activity with the HSA protein under different pH conditions.

[0285] Table 12. Affinity of humanized molecules to HSA at different pH conditions

[0286] Example 6. Detection of the effect of anti-HSA nanobody in extending half-life

[0287] 6.1. Molecular Construction and Protein Preparation

[0288] To demonstrate the half-life extension effect of anti-HSA nanobodies, multispecific antibodies were constructed in this example. The multispecific antibodies Bi-340-352, Bi-340-353, and Bi-340-354 are each independently composed of peptide chain #1 and peptide chain #2, and contain three antigen-binding domains, namely, a Fab targeting the first antigen, a nanobody (VHH1) targeting the second antigen, and a nanobody (VHH2) targeting the third antigen, wherein the VHH2 is Hu-HSA-M-27-1, Hu-HSA-59-1, Hu-HSA-PH-8-5, or a non-HSA-related VHH as a control. The structure and sequence of the multispecific antibodies are shown in Tables 13-1 and 13-2, wherein the domains in peptide chain #1 and peptide chain #2 are connected by a linker containing GGGGS.

[0289] Table 13-1 Multispecific Antibody Structure

[0290] Table 13-2 Multispecific antibody related sequences

[0291] The gene sequences encoding peptide chain #1 and peptide chain #2 of Bi-340-352, Bi-340-353, Bi-340-354, and Bi-340-356, respectively, were synthesized by Jinweizhi Company. The coding gene sequences were constructed into the pCDNA3.1 vector linearized by EcoR I / Not I double enzyme digestion using homologous recombinase (purchased from Vazyme), and the construction process was in accordance with the product instructions. The homologous recombination products of peptide chain #1 and peptide chain #2 of each of the multispecific antibodies were co-transformed into Top10 competent cells, coated with ampicillin-resistant plates, cultured overnight at 37°C, and single clones were picked for sequencing.

[0292] Using ExpiCHO TMThe plasmid was transformed into Expi-CHO cells using an expression system kit (purchased from Thermo Fisher Scientific) according to the manufacturer's instructions. After 5 days of cell culture, the supernatant was collected and purified using a KappaSelect (GE) affinity chromatography column. The specific method is as follows: Filter the sample using a syringe through a 0.2 μm sterile PES syringe filter. Equilibrate the column with 5 column volumes of equilibration buffer (20 mM PB + 0.15 M NaCl, pH 7.4) until the effluent conductivity and pH remain constant. Load the sample at a flow rate of 0.5 ml / min. After loading, rinse the column with equilibration buffer until penetration is complete and the UV value no longer decreases. Elute with elution buffer (0.1 M glycine-HCl, pH 3.0) and collect the effluent. After elution, immediately neutralize the collected antibody solution with an alkaline buffer (such as 1 M Tris / HCl, pH 8.0) to a pH stable for the antibody.

[0293] Protein purity was determined by HPLC. The HPLC method was as follows: mobile phase: 150 mM Na₂HPO₄·12H₂O, pH 7.0. Chromatographic conditions: detection wavelength: 280 nm, column temperature: 25°C, flow rate: 0.35 ml / min, detection time: 20 min, Zenix-C SEC-300 column (SEPAX 4.6 × 300 mm, 3 μm).

[0294] 6.2. Protein half-life detection

[0295] The injection dose for mice was 10 mg / kg. Blood was collected venously at 3 minutes, 30 minutes, 2 hours, 6 hours, 24 hours, 48 ​​hours, 96 hours, and 168 hours after administration. Whole blood samples were placed at 2-8°C for 30 minutes, centrifuged at 12,000 rpm for 5 minutes, and serum was collected. The resulting serum was then centrifuged at 12,000 rpm for 5 minutes at 2-8°C and stored at -80°C. ELISA was used to measure the molecular weight of free antibodies in the serum. The results are shown in Figure 1. The results show that the half-lives of molecules with anti-HSA nanobodies in mice were approximately 23.7 hours (Bi-340-352), 24.2 hours (Bi-340-353), and 10.9 hours (Bi-340-354); while the half-life of the molecule with non-HSA-related nanobodies (Bi-340-356) was approximately 1.4 hours. The results show that anti-HSA nanobodies can significantly increase the in vivo half-life of molecules.

[0296] Although the specific embodiments of the present invention have been described in detail, those skilled in the art will understand that various modifications and changes can be made to the details based on all the teachings published, and these changes are all within the scope of protection of the present invention. The entire invention is given by the appended claims and any equivalents thereof.

Claims

1. A Nanobody or antigen-binding fragment thereof capable of specifically binding to serum albumin, wherein the Nanobody or antigen-binding fragment thereof comprises: (a) CDR1 having a structure selected from the group consisting of: X1X2X3LX4YYX5 (Formula I, SEQ ID NO: 72), SGFTLDYYA (SEQ ID NO: 30), GSIWGIYH (SEQ ID NO: 37), GFTFSIYS (SEQ ID NO: 31), GSIFTFYR (SEQ ID NO: 33); (b) CDR2 having a structure selected from the group consisting of: IX6SSGGX7X8 (Formula II, SEQ ID NO: 73), ITVDGST (SEQ ID NO: 46), ISSGGSP (SEQ ID NO: 40), and ITTDTST (SEQ ID NO: 42); (c) CDR3 having a structure selected from the group consisting of: AAAX9LECRTX 10 X 11 X 12 X 13 YX 14 Y (Formula III, SEQ ID NO:74), AAATX 15 ECRGRSSSYDY (Formula IV, SEQ ID NO:75), AAALLECRVRSWPSDN (SEQ ID NO:49), AAAVLECRAAEYVNS (SEQ ID NO:54), DIRNVGGDY (SEQ ID NO:57), SPITSIFKA (SEQ ID NO:48), NVRNVERDY (SEQ ID NO:50); in, X1 is selected from the group consisting of (i) amino acid residues G, R and (ii) amino acid residues that are conservative substitutions relative to (i); X2 is selected from the group consisting of (i) amino acid residues F, A, S, E and (ii) amino acid residues that are conservative substitutions relative to (i); X3 is selected from the group consisting of (i) amino acid residues T, Q and (ii) amino acid residues that are conservative substitutions relative to (i); X4 is selected from (i) amino acid residues D, E and (ii) an amino acid residue that is a conservative substitution relative to (i); X5 is selected from (i) amino acid residue A and (ii) an amino acid residue that is a conservative substitution relative to (i); X6 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i); X7 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i); X8 is selected from the group consisting of (i) amino acid residue T and (ii) an amino acid residue that is a conservative substitution relative to (i); X9 is selected from the group consisting of (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i); X 10 selected from (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i); X 11 selected from (i) amino acid residues V, I, L and (ii) amino acid residues that are conservative substitutions relative to (i); X 12 selected from the group consisting of (i) amino acid residues R, V, T and (ii) amino acid residues that are conservative substitutions relative to (i); X 13 selected from (i) amino acid residues G, E and (ii) amino acid residues that are conservative substitutions relative to (i); X 14 selected from (i) amino acid residues D, A and (ii) amino acid residues that are conservative substitutions relative to (i); X 15 selected from (i) amino acid residues L, F and (ii) amino acid residues that are conservative substitutions relative to (i); Preferably, the Nanobody or antigen-binding fragment thereof comprises a CDR1 as shown in any one of SEQ ID NOs: 30-38; a CDR2 as shown in any one of SEQ ID NOs: 39-46; and a CDR3 as shown in any one of SEQ ID NOs: 47-59. CDR3 shown.

2. The Nanobody or antigen-binding fragment thereof according to claim 1, comprising: (a) CDR1 having the structure shown as X1X2X3LX4YYX5 (Formula I, SEQ ID NO: 72) or SGFTLDYYA (SEQ ID NO: 30); (b) CDR2 having the structure shown as IX6SSGGX7X8 (Formula II, SEQ ID NO: 73); (c) CDR3 having a structure selected from the group consisting of: AAAX9LECRTX 10 X 11 X 12 X 13 YX 14 Y (Formula III, SEQ ID NO:74), AAATX 15 ECRGRSSSYDY (Formula IV, SEQ ID NO:75), AAALLECRVRSWPSDN (SEQ ID NO:49), AAAVLECRAAEYVNS (SEQ ID NO:54); in, X1 is selected from the group consisting of (i) amino acid residues G, R and (ii) amino acid residues that are conservative substitutions relative to (i); X2 is selected from the group consisting of (i) amino acid residues F, A, S, E and (ii) amino acid residues that are conservative substitutions relative to (i); X3 is selected from the group consisting of (i) amino acid residues T, Q and (ii) amino acid residues that are conservative substitutions relative to (i); X4 is selected from (i) amino acid residues D, E and (ii) an amino acid residue that is a conservative substitution relative to (i); X5 is selected from (i) amino acid residue A and (ii) an amino acid residue that is a conservative substitution relative to (i); X6 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i); X7 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i); X8 is selected from the group consisting of (i) amino acid residue T and (ii) an amino acid residue that is a conservative substitution relative to (i); X9 is selected from the group consisting of (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i); X 10 selected from (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i); X 11 selected from (i) amino acid residues V, I, L and (ii) amino acid residues that are conservative substitutions relative to (i); X 12 selected from the group consisting of (i) amino acid residues R, V, T and (ii) amino acid residues that are conservative substitutions relative to (i); X 13 selected from (i) amino acid residues G, E and (ii) amino acid residues that are conservative substitutions relative to (i); X 14 selected from (i) amino acid residues D, A and (ii) amino acid residues that are conservative substitutions relative to (i); X 15 selected from (i) amino acid residues L, F and (ii) amino acid residues that are conservative substitutions relative to (i); Preferably, X1 is selected from amino acid residues G or R; X2 is selected from amino acid residues F, A, S or E; X3 is selected from amino acid residues T or Q; X4 is selected from amino acid residues D or E; X5 is amino acid residue A; X6 is selected from amino acid residues A or S; X7 is selected from amino acid residues A or S; X8 is amino acid residue T; X9 is selected from amino acid residues T or V; X 10 is selected from amino acid residues T or V; X 11 is selected from amino acid residues V, I or L; X 12 is selected from amino acid residues R, V or T; X 13 Selected from amino acid residues G or E; X 14 is selected from amino acid residues D or A; X 15 is selected from amino acid residues L or F; Preferably, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in any one of SEQ ID NOs: 30, 32, 34-36, 38; a CDR2 as shown in any one of SEQ ID NOs: 39, 41, 43-45; and CDR3 shown in any one of SEQ ID NOs:47, 49, 51-56, 58-59.

3. The Nanobody or antigen-binding fragment thereof according to claim 1 or 2, comprising: (a) CDR1 having the structure shown as X1X2X3LX4YYX5 (Formula I, SEQ ID NO: 72) or SGFTLDYYA (SEQ ID NO: 30); (b) CDR2 having the structure shown as IX6SSGGX7X8 (Formula II, SEQ ID NO: 73); (c) CDR3 having a structure selected from the group consisting of: AAAX9LECRTX 10 X 11 X 12 X 13 YX 14 Y (Formula III, SEQ ID NO:74), AAATX 15 ECRGRSSSYDY (Formula IV, SEQ ID NO:75), AAALLECRVRSWPSDN (SEQ ID NO:49), AAAVLECRAAEYVNS (SEQ ID NO:54); in, X1 is selected from the group consisting of (i) amino acid residues G, R and (ii) amino acid residues that are conservative substitutions relative to (i); X2 is selected from the group consisting of (i) amino acid residues F, E, S and (ii) amino acid residues that are conservative substitutions relative to (i); X3 is selected from the group consisting of (i) amino acid residue T and (ii) an amino acid residue that is a conservative substitution relative to (i); X4 is selected from (i) an amino acid residue D and (ii) an amino acid residue that is a conservative substitution relative to (i); X5 is selected from (i) amino acid residue A and (ii) an amino acid residue that is a conservative substitution relative to (i); X6 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i); X7 is selected from (i) amino acid residues A, S and (ii) amino acid residues that are conservative substitutions relative to (i); X8 is selected from the group consisting of (i) amino acid residue T and (ii) an amino acid residue that is a conservative substitution relative to (i); X9 is selected from the group consisting of (i) amino acid residues T, V and (ii) amino acid residues that are conservative substitutions relative to (i); X 10 selected from (i) amino acid residue V and (ii) an amino acid residue that is a conservative substitution relative to (i); X 11 selected from (i) amino acid residues V, I and (ii) amino acid residues that are conservative substitutions relative to (i); X 12 selected from (i) amino acid residues R, V and (ii) amino acid residues that are conservative substitutions relative to (i); X 13 selected from (i) amino acid residues G, E and (ii) amino acid residues that are conservative substitutions relative to (i); X 14 selected from (i) amino acid residue D and (ii) an amino acid residue that is a conservative substitution relative to (i); X 15 selected from (i) amino acid residues L, F and (ii) amino acid residues that are conservative substitutions relative to (i); Preferably, X1 is selected from amino acid residues G or R; X2 is selected from amino acid residues F, S or E; X3 is amino acid residue T; X4 is amino acid residue D; X5 is amino acid residue A; X6 is selected from amino acid residues A or S; X7 is selected from amino acid residues A or S; X8 is amino acid residue T; X9 is selected from amino acid residues T or V; X 10 is the amino acid residue V; X 11 is selected from amino acid residues V or I; X 12 is selected from amino acid residues R or V; X 13 Selected from amino acid residues G or E; X 14 is the amino acid residue D; X 15 is selected from amino acid residues L or F; Preferably, the nanobody or antigen-binding fragment thereof comprises: any one of SEQ ID NOs: 30, 32, 34-36 CDR1 as shown in any one of SEQ ID NOs: 39, 41, 43-45; CDR2 as shown in any one of SEQ ID NOs: 47, 49, 51, 52, 54-56, 58.

4. The Nanobody or antigen-binding fragment thereof of claim 1 , comprising: (a) CDR1 having: a sequence as shown in SEQ ID NO: 32, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 32; (b) CDR2 having: a sequence as shown in SEQ ID NO: 41, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 41; and (c) CDR3 having: a sequence as shown in SEQ ID NO: 49, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 49; Preferably, the substitution is a conservative substitution; Preferably, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 32, a CDR2 as shown in SEQ ID NO: 41, and a CDR3 as shown in SEQ ID NO:

49.

5. The Nanobody or antigen-binding fragment thereof of claim 1 , comprising: (a) CDR1 having: a sequence as shown in SEQ ID NO: 32 or 34, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence as shown in SEQ ID NO: 32 or 34; (b) CDR2 having: a sequence as shown in SEQ ID NO: 43, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 43; and (c) CDR3 having: a sequence as shown in SEQ ID NO: 52, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 52; Preferably, the substitution is a conservative substitution; Preferably, the Nanobody or antigen-binding fragment thereof comprises: (a) CDR1, which has the structure shown as X1X2X3LX4YYX5 (Formula I, SEQ ID NO: 72), wherein, X1 is an amino acid residue G; X2 is selected from (i) an amino acid residue F or E and (ii) an amino acid residue that is a conservative substitution relative to (i); X3 is an amino acid residue T; X4 is an amino acid residue D; and X5 is an amino acid residue A; (b) CDR2, which has the structure shown as IASSGGST (SEQ ID NO: 43); (c) CDR3 having the structure shown as AAAVLECRTVVRGYDY (SEQ ID NO: 52); Preferably, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 32 or 34; a CDR2 as shown in SEQ ID NO: 43; and a CDR3 as shown in SEQ ID Ns:

52.

6. The Nanobody or antigen-binding fragment thereof of claim 1 , comprising: (a) CDR1 having: a sequence as shown in SEQ ID NO: 37, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 37; (b) CDR2 having: a sequence as shown in SEQ ID NO: 46, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 46; and (c) CDR3 having: a sequence as shown in SEQ ID NO: 57, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 57; Preferably, the substitution is a conservative substitution; Preferably, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 37, a CDR2 as shown in SEQ ID NO: 46, and a CDR3 as shown in SEQ ID NO:

57.

7. The Nanobody or antigen-binding fragment thereof of claim 1 , comprising: (a) CDR1 having: a sequence as shown in SEQ ID NO: 31, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 31; (b) CDR2 having: a sequence as shown in SEQ ID NO: 40, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 40; and (c) CDR3 having: a sequence as shown in SEQ ID NO: 48, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 48; Preferably, the substitution is a conservative substitution; Preferably, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 31, a CDR2 as shown in SEQ ID NO: 40, and a CDR3 as shown in SEQ ID NO:

48.

8. The Nanobody or antigen-binding fragment thereof of claim 1 , comprising: (a) CDR1 having: a sequence as shown in SEQ ID NO: 33, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 33; (b) CDR2 having: a sequence as shown in SEQ ID NO: 42, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 42; and (c) CDR3 having: a sequence as shown in SEQ ID NO: 50, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 50; Preferably, the substitution is a conservative substitution; Preferably, the Nanobody or antigen-binding fragment thereof comprises: a CDR1 as shown in SEQ ID NO: 33, a CDR2 as shown in SEQ ID NO: 42, and a CDR3 as shown in SEQ ID NO:

50.

9. The Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 8, comprising: (1) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:41; and CDR3 as set forth in SEQ ID NO:49; (2) CDR1 as set forth in SEQ ID NO: 32 or 34; CDR2 as set forth in SEQ ID NO: 43; and CDR3 as set forth in SEQ ID NO: 52; (3) CDR1 as set forth in SEQ ID NO:37; CDR2 as set forth in SEQ ID NO:46; and CDR3 as set forth in SEQ ID NO:57; (4) CDR1 as set forth in SEQ ID NO:30; CDR2 as set forth in SEQ ID NO:39; and CDR3 as set forth in SEQ ID NO:47; (5) CDR1 as set forth in SEQ ID NO:31; CDR2 as set forth in SEQ ID NO:40; and CDR3 as set forth in SEQ ID NO:48; (6) CDR1 as set forth in SEQ ID NO:33; CDR2 as set forth in SEQ ID NO:42; and CDR3 as set forth in SEQ ID NO:50; (7) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:43; and CDR3 as set forth in SEQ ID NO:51; (8) CDR1 as set forth in SEQ ID NO:35; CDR2 as set forth in SEQ ID NO:43; and CDR3 as set forth in SEQ ID NO:52; (9) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:43; and CDR3 as set forth in SEQ ID NO:53; (10) CDR1 as set forth in SEQ ID NO:36; CDR2 as set forth in SEQ ID NO:41; and CDR3 as set forth in SEQ ID NO:54; (11) CDR1 as shown in SEQ ID NO:35; CDR2 as shown in SEQ ID NO:44; and CDR3 as shown in SEQ ID NO:55; (12) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:45; and CDR3 as set forth in SEQ ID NO:56; (13) CDR1 as set forth in SEQ ID NO:32; CDR2 as set forth in SEQ ID NO:41; and CDR3 as set forth in SEQ ID NO:52; (14) CDR1 as shown in SEQ ID NO: 32; CDR2 as shown in SEQ ID NO: 41; and CDR3 as shown in SEQ ID NO: 58; or (15) CDR1 as shown in SEQ ID NO:38; CDR2 as shown in SEQ ID NO:41; and CDR3 as shown in SEQ ID NO:

59.

10. The Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 9, comprising an amino acid sequence selected from the group consisting of: (i) a sequence as shown in any one of SEQ ID NOs: 3, 9, 24, 1-2, 7-8, 14-23, 28-29; (ii) a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) compared to the sequence shown in any one of SEQ ID NOs: 3, 9, 24, 1-2, 7-8, 14-23, 28-29; or (iii) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 3, 9, 24, 1-2, 7-8, 14-23, 28-29; Preferably, the substitutions are conservative substitutions.

11. The Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 9, which is humanized; Preferably, the Nanobody or antigen-binding fragment thereof further comprises a heavy chain framework region of a human immunoglobulin (for example, a heavy chain framework region contained in the amino acid sequence encoded by a human heavy chain germline antibody gene), which heavy chain framework region optionally comprises one or more (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) back mutations from human residues to camel residues.

12. The Nanobody or antigen-binding fragment thereof according to claim 11, comprising an amino acid sequence selected from the group consisting of: (i) a sequence as shown in any one of SEQ ID NOs: 4-6, 10-13, 25-27, and 78; (ii) a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) compared to the sequence shown in any one of SEQ ID NOs: 4-6, 10-13, 25-27, 78; or (iii) a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the sequence shown in any one of SEQ ID NOs: 4-6, 10-13, 25-27, 78; Preferably, the substitutions are conservative substitutions.

13. The Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 12, wherein The serum albumin is selected from human serum albumin (HSA), mouse serum albumin (MSA) and / or cynomolgus monkey serum albumin (CSA); Preferably, the binding of the Nanobody or antigen-binding fragment thereof to the serum albumin is pH-independent; Preferably, the Nanobody or antigen-binding fragment thereof can specifically bind to the serum albumin in the range of pH 5-8 (eg pH 5.5-7.4).

14. A polypeptide construct that specifically binds to serum albumin, comprising the Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 13, and an immunoglobulin Fc domain; Preferably, the immunoglobulin Fc domain is optionally connected to the N-terminus and / or C-terminus (e.g., the C-terminus) of the Nanobody or antigen-binding fragment thereof via a peptide linker; Preferably, the immunoglobulin Fc domain is the Fc domain of IgG (eg, the Fc domain of IgG1); Preferably, the immunoglobulin Fc domain comprises the sequence shown in SEQ ID NO: 68, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity thereto, or a sequence having one or several amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) thereto.

15. The polypeptide construct of claim 14, wherein The serum albumin is selected from human serum albumin (HSA), mouse serum albumin (MSA) and / or cynomolgus monkey serum albumin (CSA); Preferably, the binding of the polypeptide construct to the serum albumin is pH-independent; Preferably, the polypeptide construct can react with the serum albumin in the range of pH 5-8 (e.g. pH 5.5-7.4). Specific binding.

16. A fusion protein comprising the Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 13 or the polypeptide construct according to claim 13 or 14, and an additional peptide domain; Preferably, the additional peptide domain is selected from polypeptide domains having a therapeutic effect; Preferably, the additional polypeptide domain is linked to the N-terminus and / or C-terminus of said Nanobody or antigen-binding fragment thereof or said polypeptide construct, optionally via a peptide linker.

17. An isolated nucleic acid molecule encoding a Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 13, a polypeptide construct according to claim 14 or 15, or a fusion protein according to claim 16.

18. A vector comprising the nucleic acid molecule according to claim 17; preferably, the vector is a cloning vector or an expression vector.

19. A host cell comprising the nucleic acid molecule of claim 17 or the vector of claim 18.

20. A method for preparing the Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 13, the polypeptide construct according to claim 14 or 15, or the fusion protein according to claim 16, comprising culturing the host cell according to claim 19 under conditions that allow protein expression, and recovering the Nanobody or antigen-binding fragment thereof or the polypeptide construct from the culture of the cultivated host cell.

21. A bispecific or multispecific antibody comprising a Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 13 or a polypeptide construct according to claim 14 or 15; Preferably, the bispecific or multispecific antibody specifically binds to serum albumin and additionally specifically binds to one or more other targets; Preferably, the bispecific or multispecific antibody further comprises at least one second antibody having a second binding specificity for a second target; Preferably, the bispecific or multispecific antibody comprises: (i) a Nanobody or antigen-binding fragment thereof as described in any one of claims 1 to 13 or a polypeptide construct as described in claim 14 or 15 (for example, a Nanobody or antigen-binding fragment thereof or polypeptide construct comprising a sequence as shown in any one of SEQ ID NOs: 10, 4, 78) as the first antigen-specific binding domain; (ii) a second antigen comprising a light chain as shown in SEQ ID NO: 79 and a heavy chain as shown in SEQ ID NO: 80 Specific binding domain (e.g., Fab); as well as, (iii) a third antigen-specific binding domain (e.g., Nanobody VHH) as shown in SEQ ID NO: 81; Preferably, the bispecific or multispecific antibody comprises a first polypeptide chain and a second polypeptide chain, wherein: The first polypeptide chain comprises (for example, from N-terminus to C-terminus): the light chain or heavy chain (such as VH and CH1) of the second antigen-specific binding domain, the third antigen-specific binding domain, and the first antigen-specific binding domain; and the second polypeptide chain comprises (for example, from N-terminus to C-terminus): the heavy chain (such as VH and CH1) or light chain of the second antigen-specific binding domain, and the third antigen-specific binding domain; wherein the first polypeptide chain is paired with the second polypeptide chain to form a complete second antigen-specific binding domain; preferably, the respective domains in the first polypeptide chain and / or the second polypeptide chain are connected by a linker (for example, a peptide linker comprising one or more glycine and / or one or more serines); Preferably, the bispecific or multispecific antibody comprises: (1) a first peptide having a sequence as shown in SEQ ID NO: 69, and a second peptide having a sequence as shown in SEQ ID NO: 76; (2) a first peptide having a sequence as shown in SEQ ID NO: 70, and a second peptide having a sequence as shown in SEQ ID NO: 76; or, (3) a first peptide having a sequence as shown in SEQ ID NO: 71, and a second peptide having a sequence as shown in SEQ ID NO: 76; Preferably, the first peptide is present in a first peptide chain, and the second peptide is present in a second peptide chain; preferably, the first peptide chain and the second peptide chain form a complex.

22. A conjugate comprising a Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 13 or a polypeptide construct according to claim 14 or 15, and a therapeutic agent linked to said Nanobody or antigen-binding fragment thereof or polypeptide construct; Preferably, the therapeutic agent is selected from anti-tumor drugs, such as cytotoxic agents, hormonal drugs, biological response modifiers, additional antibodies or antigen-binding fragments thereof.

23. A pharmaceutical composition comprising the Nanobody or antigen-binding fragment thereof of any one of claims 1 to 13, the polypeptide construct of claim 14 or 15, the fusion protein of claim 16, the isolated nucleic acid molecule of claim 17, the vector of claim 18, the host cell of claim 19, the bispecific or multispecific antibody of claim 21, or the conjugate of claim 22; Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient; Preferably, the pharmaceutical composition comprises the Nanobody or antigen-binding fragment thereof of any one of claims 1 to 13, the polypeptide construct of claim 14 or 15, or a nucleic acid molecule, vector or host cell encoding the Nanobody or antigen-binding fragment thereof or polypeptide construct; Preferably, the pharmaceutical composition comprises the fusion protein of claim 16, or a nucleic acid molecule, vector or host cell encoding the fusion protein; Preferably, the pharmaceutical composition comprises the bispecific or multispecific antibody of claim 21, or a nucleic acid molecule, vector or host cell encoding the bispecific or multispecific antibody; Preferably, the pharmaceutical composition comprises the conjugate of claim 22.

24. Use of the Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 13, the polypeptide construct according to claim 14 or 15, the fusion protein according to claim 16, the isolated nucleic acid molecule according to claim 17, the vector according to claim 18, the host cell according to claim 19, the bispecific or multispecific antibody according to claim 21 or the conjugate according to claim 22, or the pharmaceutical composition according to claim 23 for the preparation of a medicament; Preferably, the drug can directly or indirectly participate in FcRn-mediated serum albumin circulation in the subject; Preferably, the drug shows a prolonged in vivo half-life relative to the corresponding drug lacking the Nanobody or antigen-binding fragment thereof; Preferably, the drug is a protein drug; Preferably, the subject is a mammal, such as a human, a mouse or a cynomolgus monkey.

25. A method for extending the in vivo half-life of a drug, comprising: linking the Nanobody or antigen-binding fragment thereof according to any one of claims 1 to 13 or the polypeptide construct according to claim 14 or 15 to the drug; Preferably, the extension of the in vivo half-life is relative to the in vivo half-life of the drug in the absence of the Nanobody or antigen-binding fragment thereof; Preferably, the drug is selected from macromolecular drugs (such as polypeptide drugs); Preferably, the subject is a mammal, such as a human, a mouse or a cynomolgus monkey.

Citation Information

Cited By

  • Targeted human serum albumin nano antibody and application thereof

    CN119708221A

  • Nanobody Targeting Human Serum Albumin and Its Application

    CN119708221B